COVID-19 Induced Telogen Effluvium

Overview

This study inquires about the development of Telogen effluvium following the SARS-CoV-2 infection

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Retrospective
  • Study Primary Completion Date: April 27, 2021

Detailed Description

Telogen effluvium (TE) is one of the most common causes of non-scarring alopecia. During the COVÄ°D-19 pandemic, there is an increased number of Telogen effluvium patients.This study inquires about the development of Telogen effluvium following the SARS-CoV-2 infection and correlation between the severity of covid-19 and TE.

Interventions

  • Diagnostic Test: Blood Tests
    • Evaluation of blood ferritin, hemoglobine, serum iron and serum iron binding capacity

Clinical Trial Outcome Measures

Primary Measures

  • Hair shedding
    • Time Frame: 3 months
    • Physical examination of hair and scalp, trichoscopy, hair pull test

Participating in This Clinical Trial

Inclusion Criteria

  • Sars-CoV-2 infection in the past year Exclusion Criteria:

  • Other common causes of Telogen effluvium ( such as anemia, iron deficiency, thyroid dysfunction)

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Istanbul Medeniyet University
  • Provider of Information About this Clinical Study
    • Principal Investigator: Hasan Aksoy, Specialist Dr. – Istanbul Medeniyet University
  • Overall Official(s)
    • Hasan AKSOY, Dr., Principal Investigator, Istanbul Medeniyet University
  • Overall Contact(s)
    • Umut Mert YILDIRIM, Dr., +905423383842, umutmertyildirim@gmail.com

Citations Reporting on Results

Asghar F, Shamim N, Farooque U, Sheikh H, Aqeel R. Telogen Effluvium: A Review of the Literature. Cureus. 2020 May 27;12(5):e8320. doi: 10.7759/cureus.8320. Review.

Mieczkowska K, Deutsch A, Borok J, Guzman AK, Fruchter R, Patel P, Wind O, McLellan BN, Mann RE, Halverstam CP. Telogen effluvium: a sequela of COVID-19. Int J Dermatol. 2021 Jan;60(1):122-124. doi: 10.1111/ijd.15313. Epub 2020 Nov 23.

Rizzetto G, Diotallevi F, Campanati A, Radi G, Bianchelli T, Molinelli E, Mazzanti S, Offidani A. Telogen effluvium related to post severe Sars-Cov-2 infection: Clinical aspects and our management experience. Dermatol Ther. 2021 Jan;34(1):e14547. doi: 10.1111/dth.14547. Epub 2020 Nov 23.

Cline A, Kazemi A, Moy J, Safai B, Marmon S. A surge in the incidence of telogen effluvium in minority predominant communities heavily impacted by COVID-19. J Am Acad Dermatol. 2021 Mar;84(3):773-775. doi: 10.1016/j.jaad.2020.11.032. Epub 2020 Dec 10.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.